Dr. Susanne Wiegel is Director Business Development at MorphoSys AG, a world leading biotechnology company located close to Munich, Germany. For the past seven years at MorphoSys, she was responsible for compound in- and out-licensing - as well as a variety of other BD activities - including in-licensing “MOR208” for MorphoSys’ own clinical pipeline, and out-licensing the clinical stage asset “MOR103” to Glaxo-Smith-Kline, two compound deals that were highly relevant in MorphoSys’ maturation from a pure antibody platform enterprise into a biopharmaceutical company. From 1996 to 2001, Susanne studied Biochemistry at the University of Hannover, Germany, and afterwards prepared her Ph.D. in structural biology at the Helmholtz Centre for Infection Research in Braunschweig. In 2004, Susanne joined the consulting firm McKinsey&Co where she consulted pharma and chemical companies, as well as health care providers. Afterwards, she worked in business development at MediGene AG on various portfolio management and business development topics, among those out-licensing of an anti-inflammatory drug, prior to joining MorphoSys in 2008.